Login / Signup

Ceftazidime reduces cellular Skp2 to promote type-I interferon activity.

Caixia QiaoFan HuangJiuyi HeQiuyu WuZhijin ZhengTingting ZhangYing MiaoYukang YuanXiangjie ChenQian DuYang XuDepei WuZhengyuan YuHui Zheng
Published in: Immunology (2023)
Skp2 plays multiple roles in malignant tumours. Here, we revealed that Skp2 negatively regulates type-I interferon (IFN-I)-mediated antiviral activity. We first noticed that Skp2 can promote virus infection in cells. Further studies demonstrated that Skp2 interacts with IFN-I receptor 2 (IFNAR2) and promotes K48-linked polyubiquitination of IFNAR2, which accelerates the degradation of IFNAR2 proteins. Skp2-mediated downregulation of IFNAR2 levels inhibits IFN-I signalling and IFN-I-induced antiviral activity. In addition, we uncovered for the first time that the antibiotic ceftazidime can act as a repressor of Skp2. Ceftazidime reduces cellular Skp2 levels, thus enhancing IFNAR2 stability and IFN-I antiviral activity. This study reveals a new role of Skp2 in regulating IFN-I signalling and IFN-I antiviral activity and reports the antibiotic ceftazidime as a potential repressor of Skp2.
Keyphrases
  • dendritic cells
  • immune response
  • cell proliferation
  • emergency department
  • single cell
  • induced apoptosis
  • climate change
  • endothelial cells
  • oxidative stress
  • drug induced
  • stress induced
  • pi k akt
  • adverse drug